[HTML][HTML] EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)
A Midha, S Dearden, R McCormack - American journal of cancer …, 2015 - ncbi.nlm.nih.gov
Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …
Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers
AM Chapman, KY Sun, P Ruestow, DM Cowan… - Lung cancer, 2016 - Elsevier
Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of …
Purpose Programmed cell death-1 (PD-1)/programmed cell death-ligand-1 (PD-L1) pathway-
targeted immunotherapy has beneficial therapeutic effects in pulmonary squamous cell …
targeted immunotherapy has beneficial therapeutic effects in pulmonary squamous cell …
[HTML][HTML] Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison …
Immunotherapies targeting the programmed cell death-1/programmed cell death-ligand 1
pathway have emerged as promising therapeutic strategies for lung cancer. However, the …
pathway have emerged as promising therapeutic strategies for lung cancer. However, the …
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3
ABSTRACT Programmed cell death (PD)-1/PD-1 ligand-1 (PD-L1)-targeted therapy has
emerged as a promising therapeutic strategy for lung cancer. However, whether EML4-ALK …
emerged as a promising therapeutic strategy for lung cancer. However, whether EML4-ALK …
The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers
Background Mutations of the epidermal growth factor hormone receptor (EGFR) gene have
been associated with improved treatment response and prognosis in advanced non-small …
been associated with improved treatment response and prognosis in advanced non-small …
[HTML][HTML] Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung …
Background Reinvigoration of T-cell exhaustion with antibodies has shown promising
efficacy in patients with non-small-cell lung cancer (NSCLC). However, the characteristics of …
efficacy in patients with non-small-cell lung cancer (NSCLC). However, the characteristics of …
[HTML][HTML] Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma
C Deng, Y Zhang, Z Ma, F Fu, L Deng, Y Li… - The Journal of thoracic …, 2021 - Elsevier
Background Mutation of the EGFR gene is known as a predictor for the response to EGFR
tyrosine kinase inhibitor. Although EGFR mutation status is proposed to be incorporated in …
tyrosine kinase inhibitor. Although EGFR mutation status is proposed to be incorporated in …
Lung cancer survival among never smokers
A Casal-Mourino, L Valdes, JM Barros-Dios… - Cancer letters, 2019 - Elsevier
Lung cancer incidence among never smokers has increased in recent decades with 10–
30% of all lung cancers occurring in never smokers, where exposure to residential radon is …
30% of all lung cancers occurring in never smokers, where exposure to residential radon is …
A problem with clinical T factor in the 8th TNM edition: Prognosis and EGFR mutation status of small sized lung cancers with difficulty to measure the diameter of solid …
T Matsunaga, K Suzuki, A Hattori, M Fukui, T Hayashi… - Lung Cancer, 2023 - Elsevier
Objective Clinical T factors in the 8th TNM classification of lung cancer have a practical
problem. In some cases, it is difficult to measure the size of the solid components in part …
problem. In some cases, it is difficult to measure the size of the solid components in part …